Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs High-dose Sirolimus for KHE with KMP
NCT07656909Phase 3Recruiting
- Sponsor
- Yiji Biotech
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 3 trial of sirolimus in kaposiform hemangioendothelioma (KHE), Kasabach-Merritt phenomenon (KMS), sponsored by Yiji Biotech. Started Jun 2026; status: recruiting.
02
Drugs
sirolimus
03
Conditions
kaposiform hemangioendothelioma (KHE)Kasabach-Merritt phenomenon (KMS)
Beyond the preview
Go deeper on NCT07656909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656909.